Previous Blogs

Blue West logo with Diamond

By West Technical Customer Support

June 23, 2014

One of the challenges a drug manufacturer faces is controlling the drug product at the point-of-use in a hospital or clinical environment.  Often the method of vial access is variable, leading to an increased risk of harmful patient outcomes such as stopper cores or fragments entering into the drug product, which can contribute to cardiovascular events. There are a number of causes that contribute to stopper coring and fragmentation in the field that depend primarily on the technique of the practitioner and the properties of the elastomeric closure.

Blue West logo with Diamond

By West Technical Operations

March 12, 2014

Manufacturers of sterile drug products have a long history of receiving elastomeric plungers for use  in a prefilled syringe in a sterilized, ready-to-use (RU) condition. This trend has more recently evolved to include other container closure components including, glass or plastic vials, aluminum over seals and elastomeric stoppers. When accepting RU components into a new or existing manufacturing process, it is important to consider how sterility assurance of the components will be determined.

Blue West logo with Diamond

By Tibor Hlobik

March 05, 2014

Many of the top-selling biologic drug products will soon come off-patent. As a result, according to IMS, the biosimilar market is expected to reach between US$1.9-2.6 billion by 2015.

Blue West logo with Diamond

By Joanne Neizer

January 14, 2014

Natural Rubber Latex (NRL) has been a topic of concern in the pharmaceutical industry since the early 1990s. Concerns with allergens prompted labeling guidelines to ensure safe patient treatment. West Pharmaceutical Services’ elastomeric formulations for injectable packaging components for vials and syringes may contain Dry Natural Rubber (DNR) in the form of crepe, but the formulations do not incorporate NRL.